Smith Marcus, Pappy Reji, Hennebry Thomas A
Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA.
Tex Heart Inst J. 2011;38(4):392-7.
Chronic occlusions are present in up to 40% of patients who undergo treatment for symptomatic peripheral arterial disease. The primary difficulty encountered during the treatment of chronic occlusions is inability to re-enter the true lumen after subintimal crossing of the occlusion. Two devices have been designed to mitigate this limitation via controlled re-entry. Herein, we report our experience with the Outback LTD catheter and the Pioneer Plus Catheter PPlus 120 in re-entering the true arterial lumen during percutaneous intentional extraluminal revascularization for peripheral chronic occlusions involving the superficial femoral artery. In reviewing our peripheral interventions performed from February 2006 through February 2009, we evaluated angiograms, patients' characteristics, presentations, types of lesions, procedural successes, complications, and symptom-free intervals. The total study population consisted of 23 patients. The Outback catheter was used in 15 patients and the Pioneer catheter in 8 patients.The procedure was successful in all 8 Pioneer cases (100%) and in 13 of the 15 Outback cases (87%). All 8 (100%) of the patients in the Pioneer group and 12 of the 14 patients in the Outback group (86%) remained asymptomatic at an average of 12 months. Overall, there were no procedural complications, amputations, or deaths. This single-center experience demonstrates that the Outback and Pioneer re-entry catheters are safe and effective in managing peripheral chronic occlusions, with an average symptom-free interval of 12 months. This management strategy proves to be reasonable when standard techniques fail to achieve true lumen re-entry.
在接受有症状外周动脉疾病治疗的患者中,高达40%存在慢性闭塞。慢性闭塞治疗过程中遇到的主要困难是在闭塞内膜下穿过之后无法重新进入真腔。已设计出两种装置,通过可控的重新进入来减轻这一限制。在此,我们报告我们使用Outback LTD导管和先锋加导管PPlus 120在经皮有意腔外血管重建治疗涉及股浅动脉的外周慢性闭塞时重新进入动脉真腔的经验。在回顾我们从2006年2月至2009年2月进行的外周介入治疗时,我们评估了血管造影、患者特征、临床表现、病变类型、手术成功率、并发症及无症状间隔时间。研究总人群包括23例患者。15例患者使用了Outback导管,8例患者使用了先锋导管。8例先锋导管治疗的病例全部成功(100%),15例Outback导管治疗的病例中有13例成功(87%)。先锋组的所有8例患者(100%)和Outback组14例患者中的12例(86%)在平均12个月时仍无症状。总体而言,无手术并发症、截肢或死亡情况。这一单中心经验表明,Outback和先锋重新进入导管在处理外周慢性闭塞方面安全有效,平均无症状间隔时间为12个月。当标准技术无法实现真腔重新进入时,这种管理策略被证明是合理的。